Seeking Alpha

GlaxoSmithKline (GSK) and Theravance (THRX) say the new drug application for the once-daily...

GlaxoSmithKline (GSK) and Theravance (THRX) say the new drug application for the once-daily investigational medicine FF/VI for patients with chronic obstructive pulmonary disease has been accepted by the FDA, indicating the application is sufficiently complete to permit a substantive review.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs